InBrain Pharma

Executive Summary

InBrain Pharma is a French biotechnology company leveraging targeted brain infusion to deliver therapeutics directly to the central nervous system for neurological disorders, with a primary focus on Parkinson's disease. Founded in 2012 and currently at the pre-clinical stage, the company aims to personalize treatment and improve outcomes by overcoming the blood-brain barrier. Its proprietary approach could offer significant advantages over systemic delivery, potentially reducing side effects and enhancing efficacy. While InBrain Pharma has not yet advanced to clinical trials, its technology addresses a critical unmet need in neurodegenerative diseases, positioning it for potential partnerships or further development as it progresses toward the clinic.

Upcoming Catalysts (preview)

• H1 2027Preclinical proof-of-concept data in Parkinson's disease models60% success
• H2 2026Series A or government grant funding announcement70% success
• 2027Collaboration or licensing deal with a larger pharma for CNS delivery platform40% success